George Vargas, MD
Endocrinology, Diabetes & Metabolism · Pembroke Pines, FLNPI 1124006606
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $240 of the $295 with a category attached, or 81.4%. It is spread thinly across 9 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $182, 4.9 times the $37 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in FL, where the typical reported total is $3,445.
Across 15 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$65
- Abbott$64
- Xeris Pharmaceuticals, Inc.$33
- Sequel Med Tech, LLC$26
- Medtronic$25
- Neurocrine Biosciences, Inc.$25
- plus $56 from 3 others
What the payments were for
- Food & beverage$24081%
- Education$5519%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mannkind Corporation | 2 | $65 |
| Abbott | 4 | $64 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Sequel Med Tech, LLC | 1 | $26 |
| Medtronic | 2 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $24 |
| Dexcom, Inc. | 1 | $21 |
| Covidien LP | 1 | $11 |
How this compares
$295 in reported general payments places this provider in the 15th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Novolog FlexpenInsulin Aspart | 144 | $66,642 |
| OzempicSemaglutide | 59 | $64,345 |
| RybelsusSemaglutide | 31 | $63,780 |
| JanuviaSitagliptin Phosphate | 41 | $52,400 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 194 | $52,134 |
| JardianceEmpagliflozin | 25 | $32,099 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 64 | $28,955 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $26,757 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 143 | $20,044 |
| MounjaroTirzepatide | 18 | $18,749 |
| TradjentaLinagliptin | 17 | $17,327 |
| SynthroidLevothyroxine Sodium | 128 | $16,692 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $9,431 |
| Novolin R FlexpenInsulin Regular, Human | 11 | $6,485 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 36 | $3,747 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Pembroke Pines
- Fidel HenriquezPembroke Pines$548K
- Andres HenriquezPembroke Pines$136K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.